IntrinsicIntrinsic
← All summaries

ALUMIS INC.

ALMS
Financials & Chart →

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies to replace broad immunosuppression, primarily through its two Tyrosine Kinase 2 (TYK2) inhibitors, envudeucitinib (envu) and A-005 . The company was incubated by Foresite Labs and incorporated in January 2021, changing its name to Alumis Inc. in January 2022 . Alumis leverages a proprietary precision data analytics platform, biological insights, and experienced research and development experts to understand disease pathologies, accelerate R&D, and increase clinical success probability .

The core business model of Alumis is centered on the research, development, and potential commercialization of novel biopharmaceutical product candidates for immune-mediated diseases . The company generates revenue primarily through collaboration agreements, such as the Kaken Collaboration Agreement, and aims to generate future revenue from product sales upon regulatory approval and commercialization . Alumis has not yet generated any revenue from product sales and has incurred substantial losses since its inception . Its primary customer segments, upon commercialization, would be patients suffering from immune-mediated diseases like moderate-to-severe plaque psoriasis (PsO) and systemic lupus erythematosus (SLE) .

Alumis's product pipeline is built around its TYK2 franchise and includes an acquired monoclonal antibody. The most advanced product candidate is envu, a potent, highly selective, allosteric TYK2 inhibitor, which is currently in Phase 2 open-label extension (OLE) and Phase 3 long-term extension (LTE) trials for PsO, and a Phase 2 clinical trial for SLE . The company plans to submit a New Drug Application (NDA) for envu in PsO to the FDA in the second half of 2026 . Envu is designed to maximize target inhibition and optimize tolerability, demonstrating intrinsic selectivity for TYK2 over other JAK family members, optimized molecular properties, predictable pharmacokinetics, maximal target inhibition at the 40 mg BID dose, and a favorable clinical tolerability profile with lower frequency of skin rashes compared to first-generation TYK2 inhibitors .

The second TYK2 product candidate, A-005, is a CNS-penetrant allosteric TYK2 inhibitor, intended for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis (MS), Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), optic neuritis, neuromyelitis optica, and Parkinson’s disease . A-005 initiated its Phase 1 program in healthy volunteers in April 2024, with initial positive results reported in December 2024, showing it was well tolerated with no serious adverse events (SAEs) . In connection with the ACELYRIN Merger, Alumis acquired lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for the potential treatment of Thyroid Eye Disease (TED) . The company is evaluating the development program for lonigutamab and its potential differentiation in a capital-efficient manner . Beyond TYK2, Alumis is also discovering and advancing earlier-stage product candidates, such as interferon regulatory factor 5 (IRF5) inhibitors, across various stages of development from lead identification to lead optimization .

For the fiscal year ended December 31, 2025, Alumis reported a net loss of $243.3 million , compared to a net loss of $294.2 million for the year ended December 31, 2024 . As of December 31, 2025, the company had an accumulated deficit of $901.9 million and held $308.5 million in cash, cash equivalents, and marketable securities . The company's operating losses are primarily driven by research and development efforts and general and administrative costs .

A significant operational development during the period was the completion of the ACELYRIN Merger on May 21, 2025 . This common stock transaction was valued at approximately $238.1 million and involved the issuance of 48,653,549 shares of Alumis common stock to acquire net assets with a fair value of $426.0 million . Additionally, Alumis reported positive topline results in the first quarter of 2026 from its pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in PsO, where envu met all primary and secondary endpoints with high statistical significance . In June 2024, the company discontinued its proof-of-concept Phase 2a clinical trial of envu in patients with non-infectious uveitis due to efficacy results not meeting clinical thresholds for success .

Business Outlook

Alumis plans to submit a New Drug Application (NDA) for envu in PsO to the FDA in the second half of 2026 . The company also expects to report topline results from its Phase 2 clinical trial of envu in systemic lupus erythematosus (SLE) in the third quarter of 2026 . For its second TYK2 product candidate, A-005, Alumis intends to provide an update on a Phase 2 trial commencement following the completion of its current indication evaluation .

A major growth area for Alumis is maximizing the opportunity presented by envu's differentiated pharmacological profile and breadth of potential indications . The company believes envu is a foundational asset, with genetic and biologic data supporting TYK2 inhibition across multiple diseases, including current clinical programs in PsO and SLE, and future clinical ambitions . Alumis intends to expand clinical development of envu to additional therapeutic areas and indications where TYK2 inhibition and its differentiated profile could offer significant patient improvements . The positive topline results from the Phase 3 ONWARD1 and ONWARD2 trials in PsO, where envu achieved superior skin clearance compared to placebo (p < 0.0001) on co-primary endpoints of PASI 75 and sPGA 0/1 at Week 16, and also compared to apremilast (p<0.0001) on all PASI endpoints at Week 24, support this growth strategy .

Another significant growth vector is the expansion of the TYK2 franchise with A-005, an allosteric TYK2 inhibitor designed to penetrate the CNS for neuroinflammation . There is strong biological rationale and compelling genetic evidence for TYK2's role in neuroinflammatory and neurodegenerative diseases, including MS . Alumis believes TYK2 inhibition has potential utility in various conditions such as MS, Alzheimer’s disease, ALS, optic neuritis, neuromyelitis optica, and Parkinson’s disease . The company also aims to discover and advance earlier-stage product candidates into clinical development, utilizing its precision approach to identify and develop assets like IRF5 inhibitors, which could be used as monotherapy or in combination with the TYK2 franchise .

Operationally, Alumis expects its expenses to increase significantly as it continues to progress the development of its product candidates in multiple clinical trials in parallel, prepares for the NDA submission for envu in PsO, explores additional indications, hires more clinical and scientific personnel, and expands its intellectual property rights . The company also anticipates increased costs related to royalty, milestone, or other payments under existing and future license agreements, identifying and acquiring new technologies, seeking regulatory and marketing approvals, and procuring manufacturing and supply chain capacity, including commercial manufacturing readiness and scale-up .

Regarding capital allocation, Alumis has primarily funded its operations through equity offerings, debt financings, and collaboration agreements . As of December 31, 2025, the company had $308.5 million in cash, cash equivalents, and marketable securities . In March 2026, Alumis entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., allowing it to offer and sell up to $300.0 million of its common stock from time to time . The company does not anticipate declaring or paying any cash dividends in the foreseeable future, intending to retain all future earnings to finance business growth and development .

Management has explicitly flagged several structural headwinds and execution risks. The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, having incurred substantial losses and anticipating increasing losses for the foreseeable future . Enrollment and retention of participants in clinical trials is an expensive and time-consuming process, made difficult by factors outside the company's control, including competition for recruiting participants . Alumis will require substantial additional financing to achieve its goals, and failure to obtain capital on acceptable terms could delay, limit, reduce, or terminate product development or future commercialization efforts . Preclinical and clinical development is lengthy, expensive, and uncertain, with earlier results not always predictive of future trial outcomes, potentially leading to additional costs or delays . The company's clinical trials may reveal serious adverse events (SAEs) and significant adverse events (AEs) not seen previously, which could delay or prevent regulatory approval or market acceptance .

Geographic, regulatory, and macro factors identified as constraints include intense competition from large and specialty pharmaceutical and biotechnology companies, many with greater resources and approved therapies . The company is subject to various risks related to the acquisition and integration of ACELYRIN . The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable . International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, financial condition, results of operations, and growth prospects, particularly given that most suppliers are located outside the United States, in countries like India and Taiwan . The company's future growth depends partly on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and uncertainties . Unstable economic and market conditions, including inflation, rising interest rates, and labor shortages, may have serious adverse consequences on the business, financial condition, and stock price .

Risk Factors

Alumis faces material risks including substantial and increasing net losses, with an accumulated deficit of $901.9 million as of December 31, 2025 , and a need for significant additional financing, which if not obtained on acceptable terms, could delay or terminate product development . Clinical trials are lengthy, expensive, and uncertain, with potential for serious adverse events (SAEs) and adverse events (AEs) that could delay or prevent regulatory approval or market acceptance of product candidates like envu and A-005 . The company operates in a highly competitive biopharmaceutical industry against entities with greater financial and technical resources, and its business is highly dependent on the success of envu, which may not complete development, receive regulatory approval, or be successfully commercialized . Regulatory approval processes are lengthy and unpredictable, and ongoing obligations post-approval, along with potential labeling restrictions or market withdrawals, could result in significant additional expense or penalties . International trade policies, including tariffs, such as the 10% baseline global tariff imposed in April 2025 and higher "reciprocal" tariffs in August 2025 on territories including EU member states and South Korea, could increase research and development expenses and supply chain complexity, particularly as most suppliers are located outside the United States . Data privacy and security laws, such as the EU GDPR and UK GDPR, impose strict requirements with potential fines of up to €20 million or £17.5 million, or 4% of annual global revenue, whichever is greater, for non-compliance, increasing compliance costs and legal risks . The company's operations are predominantly concentrated in California, exposing it to risks from natural disasters like wildfires and earthquakes .

Management Priorities

Management's message to shareholders conveys a clear mission to significantly improve patient lives by replacing broad immunosuppression with targeted therapies, emphasizing a precision approach leveraging data analytics, biological insights, and experienced R&D experts . They highlight the positive topline results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in PsO, where envu met all primary and secondary endpoints with high statistical significance, achieving superior skin clearance compared to placebo (p < 0.0001) on co-primary endpoints of PASI 75 and sPGA 0/1 at Week 16, and also compared to apremilast (p<0.0001) on all PASI endpoints at Week 24 . Management plans to submit an NDA for envu in PsO to the FDA in the second half of 2026 and expects to report topline results for envu in SLE in the third quarter of 2026 . Key strategic priorities include maximizing the opportunity presented by envu's differentiated pharmacological profile and breadth of potential indications, expanding the TYK2 franchise with A-005 for neuroinflammation, and discovering and advancing earlier-stage product candidates into clinical development . They also emphasize leveraging their precision approach to increase development speed, probability of success, and therapy precision, and evaluating strategic collaborations to maximize the global impact of their product candidates .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 7, MD&A — Overview
  6. [6] Item 7, MD&A — Overview
  7. [7] Item 1, Business — Our TYK2 Franchise
  8. [8] Item 1, Business — Overview
  9. [9] Item 1, Business — Overview
  10. [10] Item 1, Business — Envu: Our Allosteric TYK2 Inhibitor
  11. [11] Item 1, Business — Our Product Candidates and Pipeline
  12. [12] Item 1, Business — Development
  13. [13] Item 1, Business — Our Product Candidates and Pipeline
  14. [14] Item 1, Business — Our Product Candidates and Pipeline
  15. [15] Item 1, Business — Our Discovery Programs
  16. [16] Item 7, MD&A — Overview
  17. [17] Item 7, MD&A — Overview
  18. [18] Item 7, MD&A — Overview
  19. [19] Item 7, MD&A — Overview
  20. [20] Item 7, MD&A — Overview
  21. [21] Item 1, Business — ACELYRIN Merger
  22. [22] Item 1, Business — ACELYRIN Merger
  23. [23] Item 1, Business — Envu for the Treatment of PsO
  24. [24] Item 1A, Risk Factors — Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.
  25. [25] Item 7, MD&A — Overview
  26. [26] Item 7, MD&A — Overview
  27. [27] Item 1, Business — A-005: Our CNS-Penetrant Allosteric TYK2 Inhibitor
  28. [28] Item 1, Business — Our Strategy
  29. [29] Item 1, Business — Our Strategy
  30. [30] Item 1, Business — Our Strategy
  31. [31] Item 1, Business — Envu for the Treatment of PsO
  32. [32] Item 1, Business — Our Strategy
  33. [33] Item 1, Business — Our Strategy
  34. [34] Item 1, Business — Role of TYK2 in Neuroinflammatory and Neurodegenerative Diseases
  35. [35] Item 1, Business — Our Strategy
  36. [36] Item 7, MD&A — Overview
  37. [37] Item 7, MD&A — Overview
  38. [38] Item 7, MD&A — Overview
  39. [39] Item 7, MD&A — Overview
  40. [40] Item 7, MD&A — Overview
  41. [41] Item 5, Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividend Policy
  42. [42] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Capital
  43. [43] Item 1A, Risk Factors — Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients, the availability of competitive products and significant competition for recruiting participants in clinical trials.
  44. [44] Item 1A, Risk Factors — We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce or terminate our product development or future commercialization efforts.
  45. [45] Item 1A, Risk Factors — Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.
  46. [46] Item 1A, Risk Factors — Our clinical trials may reveal SAEs and AEs and may result in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of envu, A-005 or any future product candidates.
  47. [47] Item 1A, Risk Factors — We face competition from entities that have made substantial investments into the rapid development of competitor treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in our current indications.
  48. [48] Item 1A, Risk Factors — We are subject to various risks related to the acquisition of ACELYRIN.
  49. [49] Item 1A, Risk Factors — The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  50. [50] Item 1A, Risk Factors — International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and growth prospects.
  51. [51] Item 1A, Risk Factors — Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
  52. [52] Item 1A, Risk Factors — Unstable economic and market conditions may have serious adverse consequences on our business, financial condition and stock price.
  53. [53] Item 1A, Risk Factors — We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and have incurred substantial losses since our inception and anticipate incurring substantial and increasing losses for the foreseeable future.
  54. [54] Item 1A, Risk Factors — We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce or terminate our product development or future commercialization efforts.
  55. [55] Item 1A, Risk Factors — Our clinical trials may reveal SAEs and AEs and may result in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of envu, A-005 or any future product candidates.
  56. [56] Item 1A, Risk Factors — We face competition from entities that have made substantial investments into the rapid development of competitor treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in our current indications.
  57. [57] Item 1A, Risk Factors — Even if we receive regulatory approval for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  58. [58] Item 1A, Risk Factors — International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and growth prospects.
  59. [59] Item 1A, Risk Factors — We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules; contractual obligations; policies; and other obligations related to data privacy and security. Our (including the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences for our business, results of operations and financial condition.
  60. [60] Item 1A, Risk Factors — Our operations are predominantly concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by a wildfire, earthquake or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  61. [61] Item 7, MD&A — Overview
  62. [62] Item 1, Business — Envu for the Treatment of PsO
  63. [63] Item 7, MD&A — Overview
  64. [64] Item 7, MD&A — Overview
  65. [65] Item 1, Business — Our Strategy
  66. [66] Item 1, Business — Our Strategy

Analysis on 5/19/2026